S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
NASDAQ:VIE

Viela Bio (VIE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$53.01
$53.01
50-Day Range
$52.92
$53.20
52-Week Range
$25.02
$65.00
Volume
N/A
Average Volume
1.07 million shs
Market Capitalization
$2.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

VIE stock logo

About Viela Bio Stock (NASDAQ:VIE)

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.


VIE Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
ArriVent BioPharma Files For IPO
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
8-K: Horizon Therapeutics Public Ltd Co
See More Headlines
Receive VIE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viela Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2021
Today
3/03/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VIE
CIK
N/A
Fax
N/A
Employees
166
Year Founded
N/A

Profitability

Net Income
$-86,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$50 million
Book Value
$7.14 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.91 billion
Optionable
Not Optionable
Beta
0.43
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Zhengbin Yao (Age 55)
    Chairman, Pres & CEO
    Comp: $846.75k
  • Mr. Mitchell Chan (Age 40)
    Chief Financial Officer
    Comp: $420.34k
  • Dr. Jörn Drappa M.D. (Age 56)
    Ph.D., Chief Medical Officer and Head of R&D
    Comp: $637.39k
  • Mr. James Paul Kastenmayer J.D. (Age 49)
    Ph.D., Gen. Counsel & Company Sec.
  • Ms. Kate Surdez
    Sr. VP & Head of HR
  • Ms. Rachel Ettinger
    Sr. Director & Head of Research
  • Mr. Bill Rees
    Sr. Director & Head of Translational Science
  • Mr. Ted Phillips
    VP & Head of Clinical Operations
  • Mr. Dewei She
    Sr. Director and Head of Biostatistics, Data Management, & Programming
  • Mr. Lee Levin
    Sr. Director & Head of Quality














VIE Stock Analysis - Frequently Asked Questions

How were Viela Bio's earnings last quarter?

Viela Bio, Inc. (NASDAQ:VIE) announced its earnings results on Sunday, February, 28th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.70) by $0.10. The firm had revenue of $9.34 million for the quarter, compared to analyst estimates of $5.10 million.

When did Viela Bio IPO?

(VIE) raised $150 million in an initial public offering on Thursday, October 3rd 2019. The company issued 7,500,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

This page (NASDAQ:VIE) was last updated on 3/3/2024 by MarketBeat.com Staff